

6. **Literaturverzeichnis**

- [1] Abeloff, M. D.; Lichter, A. S.; Niederhuber, J. E. et al.: Breast. Clinical Oncology. (Ed. Abeloff, M. D.; Armitage, J. O.; Lichter, A. S. and Niederhuber, J. E.) 2051-2159, Churchill Livingstone, New York (2000)
- [2] Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland. Häufigkeiten und Trends., 1-1044, Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland; Robert Koch Institut, Berlin, Saarbrücken (2002)
- [3] Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (Hrsg. In Zusammenarbeit mit dem Robert-Koch-Institut) Krebs in Deutschland – Häufigkeiten und Trends. 3. Erw. u. akt. Auflage, Saarbrücken (2002)
- [4] Arora, N. K.; Gustafson, D. H.; Hawkins, R. P., et al.: Impact of surgery and chemotherapy in younger women with breast cancer. Cancer 92, 1288-1298 (2001)
- [5] Arriagada, R.; Le, M.G.; Rochard, F.; Contesso, G.: Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J. Clin. Oncol. 14, 1558-1564 (1996)
- [6] Bartelink, H.; Horiot, J. C.; Poortmans, P.; Struikmans, H.; Van den Bogaert, W.; Barillot, I.; Fourquet, A.; Borger, J.; Jager, J.; Hoogenraad, W.; Collete, L.; Pierart, M.: European Organization für Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N. Engl. J. Med. 8; 345: 1378-1387 (2001)

- [7] Becker, N.; Wahrendorf, J.: Krebsatlas der Bundesrepublik Deutschland 1981 – 1990, 3. Aufl. Springer, Berlin (1997)
- [8] Benson, K.: A comparison of observational studies and randomized clinical trials. *N. Engl. J. Med.* 342, 1878-1886 (2000)
- [9] Berg, P. A.; Stein, G. M.: Beeinflußt die Misteltherapie die Abwehr epithelialer Tumoren? Eine kritische immunologische Analyse. *Dtsch. Med. Wschr.* 125, 339-345 (2001 b)
- [10] Berg, P. A.; Stein, G. M.: Does mistletoe therapy influence the defense against epithelial tumors? A critical immunologic analysis. *Dtsch. Med. Wochenschr.* 126, 339-345 (2001)
- [11] Berger, A.: Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy and randomized controlled trials, *Oncol. Nurs Forum*, 25, 51- 62 (1998)
- [12] Berrino, F.; Sant, M.; Verdecchia, A. et al.: Survival of Cancer Patients in Europe – The Eurocare Study IARC Publ. 132, Lyon (1995)
- [13] Beuth, J.; Ko, H. L.; Gabius, H.-J.; Pulverer, G.: Influence of treatment with immunomodulatory effective dose of β -galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. *In vivo*, 29-32 (1991)

- [14] Beuth, J.; Ost, B.; Pakdaman, A.; Rethfeldt, E.; Bock, P. R.; Hanisch, J.; Schneider, B.: Impact of complementary oral radiation application on the postoperative treatment results of breast cancer patients – results of an epidemiological multicentre retrospective cohort study. *Cancer Chemother. Pharmacol.* 47, 45-54 (2001)
- [15] Beuth, J.; Stoffel, B.; Ko. H.L. et al.: Immunaktive Wirkung verschiedener Mistlektin-Dosierungen in Mamma-Carcinom-Patientinnen, *Arzneim. Forsch/Drug Res.* 45, 505-507 (1995)
- [16] Bloksma, N. et al.: Stimulation of Humoral and Cellular Immunity by *Viscum album* Preparations. *Planta medica* 46 (4), (1982)
- [17] Bocci, V.: Mistletoe (*Viscum album*) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. *J. Biol. Regul. Homeost. Agents* 7, (1993)
- [18] Borelli, E.: Valutazione della qualità di vita in pazienti affette da adenocarcinoma mammario sottoposte a radiati con *Viscum album*. *La Medicina Biologica*, 27-30 (1999)
- [19] Burger, A. M.; Mengs, U.; Schüler, J. B. et al.: Recombinant mistletoe lectin (rML) is a potent inhibitor of tumor cell growth in vitro and in vivo. *Proc. Amer. Assoc. Cancer Res.* 40, 399 (1999)
- [20] Burger, A. M.; Mengs, U.; Schüler, J. B.; Zinke, H.; Lentzen, H. and Fiebig, H.: Recombinant mistletoe lectin (rML) is a potent inhibitor of tumor growth in vitro and in vivo. *Proc. Amer. Ass Cancer Res* 40, 399 (abstract 2639), (1999)

- [21] Büssing, A.: Biological and pharmacological properties of *Viscum Album* L. Mistletoe. The Genus *Viscum*. (Ed. Büssing, A.) 123-183, Harwood academic publishers, Amsterdam (2000)
- [22] Büssing, A.: Induction of apoptosis by the mistletoe lectins: A review on the mechanisms of cytotoxicity mediated by *Viscum album* L. *Apoptosis* 1, 25-32 (1996)
- [23] Büssing, A.: Mistel (*Viscum album*) – anthroposophischer und phytotherapeutischer Ansatz In: Münstedt, K. (Hrsg.): Ratgeber unkonventionelle Krebstherapien. ECOMED Verlag, Landsberg, 184-199 (2003)
- [24] Büssing, A.: Pharmakologische Wirkungen von Mistelextrakten In: Fintelman, V. (Hrsg.): Onkologie auf anthroposophischer Grundlage. Johannes, M. Mayer-Verlag, Stuttgart, Kapitel 3.2.4.1, 1-40 (2002)
- [25] Büssing, A.; Schietzel, M.: Apoptosis induced properties of *Viscum album* from different host tress, correlate with their content of toxic mistletoe lectins. *Anticancer Researce* 19, 23-28 (1999)
- [26] Cassileth, B.: Complementary and alternative cancer medicine. *J Clin Oncol* 17, 11s: 44-52, (1999)
- [27] Coebergh, J. W. W.; Sant, M.; Berrino, F.; Verdecchia, A.: Survival of Adult Cancer Patients in Europe Diagnosed from 1978-1989: the Eurocare II Study, *Eur J Cancer* 34, 2137-2278 (1998)
- [28] Coleman, M. P.; Esteve, J.; Damiecki, P. et al.: Trends in Cancer Incidence and Mortality, IARC Publ. 121, Lyon (1993)

- [29] Concato, J.: Randomized, controlled trials, observational studies, and the hierarchy of research design. *N Engl J Med* 342, 1887-1892 (2000)
- [30] Coulon, A. Mosbach, A., Lopez, A., Santerau, A. M., Schaller, G. Urech, K. Pouge, P, Darbon, H., (2003): Comparative membrane interaction study of viscotoxin A3, *Biochim, Biophys. Acta* 1559:145-159
- [31] Diab, S. G.; Hilsenbeck, S. G.; de Moor, C.; Clark, G. M.; Osborne, C. K.; Ravdin, P. M.; Elledge, R. M.: Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with radiation. *J. Clin. Oncol.* 16, 1655-1660 (1998)
- [32] Dold, U.; Edler, L.; Mäurer, H. Ch.; Müller-Wening, D.; Sakellariou, B.; Trendelenburg, F. and Wagner, G.: [Additive cancer therapy of advanced non-small cell bronchial carcinoma. A multicentre controlled study for evaluation of efficacy of Iscador and Polyerga]. *Krebszusatztherapie beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom. Multizentrische kontrollierte Studie zur Prüfung der Wirksamkeit von Iscador und Polyerga*, Thieme Verlag, Stuttgart, New York (1991)
- [33] Dunst, J.; Steil, B.; Furch, S.; Fach, A.; Lautenschlager, C.; Diestelhorst, A.; Lampe, D.; Kolbl, H.; Richter, C.: Prognostic significance of local radiation in breast cancer after postmastectomy radiotherapy. *Strahlenther-Onkol.* 177, 504-510 (2001)
- [36] Edler, L.: Mistel in der Krebstherapie: Fragwürdige Ergebnisse neuerer klinischer Studien, *Deutsches Ärzteblatt* 101 (1/2), A 44-49 (2004)

- [37] Edler, L.: Randomized clinical studies with mistletoe in cancer: results, experience and perspectives. [Randomisierte klinische Studien zur Misteltherapie bei Krebs: Ergebnisse, Erfahrungen und Perspektiven]. In Grundlagen der Misteltherapie. (Ed. Scheer, R.; Becker, H. and Berg, P. A.) Hippokrates Verlag, Stuttgart, Germany (1996)
- [38] Eifel, P.; Axelson, J.A.; Costa, J.; et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000 J. Nat. Cancer Inst 93, 979-989 (2001)
- [39] Ernst, E.: Mistletoe for cancer? Eur. J. Cancer 37, 9-11 (2001)
- [40] Ernst, E.; Cassileth, B. R.: How useful are unconventional cancer treatments? Eur. J. Cancer 35, 1608-1613 (1999)
- [41] Feinstein, A. R.: Clinical Epidemiology. The Architecture of Clinical Research, 1-811, W. B. Saunders Company, Philadelphia (1985)
- [42] Fellmer, Ch., Fellmer, K.E.: Nachbehandlung bestrahlter Karzinome mit dem Viscum album Präparat "Iscador" Krebsarzt 21, 1966),1174-184
- [43] Ferlay, J.; Bray, F.; Sankila, R.; Parkin, M. D.: EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1995, version 2.0., IARC Cancer Base No. 4. Lyon, IARC Press (1999)
- [44] Fadiati, A.; Limberg, R. Scheithe, K.: Mistletoe-lectin in Patients with tumor [Mistel-Lektin bei Patienten mit Tumorerkrankungen]. Medizin im Bild 1, 1-8 (1998)

- [45] Fisher, B., Bryant, J., Wolmark, N. et. al.: Re-analysis and results after 12 years of follow up in a randomized clinical trial comparing total mastectomy with lymphectomy with or without irradiation in the treatment of breast cancer, *N. Engl. J. Med.* 333:1456-1461 (1995)
- [46] Fischer, B.; Bryant, J.; Wolmark, N.; Mamounas, E.; Brown, A.; Fisher, E. R.; Wickerham, D. L.; Begovic, M.; DeCillis, A.; Robidoux, A.; Margolese, R. G.; Cruz, A. B. Jr.; Hoehn, J. L.; Lees, A. W.; Dimitrov, N.V.; Bear, H. D.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J. Clin. Oncol.* 16, 2672-2685 (1998)
- [47] Fischer, S.; Scheffler, A.; Kabelitz, D.: Stimulation of the specific immune system by radiation extracts. *Anticancer Drugs* 8, Suppl. 1, 33-37 (1997)
- [48] Fletcher, G.H.; Mc Neese, M. D.; Oswald, M. J.: Long-range results for breast cancer patients treated by radical mastectomy and postoperative radiation without adjuvant chemotherapy: An update. *Int J Radiat Oncol. Biol. Phys.* 17, 11-14 (1989)
- [49] Forrest, A. P.; Stewart, H. J.; Everington, D.; Prescott, R. J.; Mc Ardle, C. S.; Harnett, A. N.; Smith, D. C.; George, W. D.: Randomised controlled trial of conservation therapy for breast Cancer: 6-year analysis of the Scottish trial. *Scottish Cancer Trials Breast Group. Lancet* 348, 708-713 (1996)
- [50] Fritz, P.; Seizer-Schmidt, A.; Mürdter, t.; Kroemer, H.; Aulitzky, W.; Andre, S.; Gabius, H. J.; Friedel, G.; Toomes, H.; Siegle, I.: Ligands for Visum album agglutinin and galectin-1 in human lung cancer: Is there any prognostic relevance? *Acta histochem.* 101, 239-253 (1999)

- [52] Ganz, P. A.: Impact of tamoxifen adjuvant therapy. J. Nat. Cancer Inst. Monographs 30, 130-134 (2001)
- [53] Ganz, P. A.; Desmond, K. A.; Leedham, B. J.; et al.: Quality of life in long-term, disease free survivors of breast cancer: a follow up study. J. Natl. Cancer Inst. 94, 39-49 (2002)
- [54] German Cochrane Center. Evidence hierarchy. (2002). Ref. Type: Internet Communication
- [55] German Professional Society of Epidemiology. Guidelines and recommendations for insuring good epidemiological practice (GEP). Gesundheitswesen 62, 295-299 (2000)
- [56] Goldhirsch A.; Glick J. H.; Gelber R. D.; et al.: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J. Clin. Oncol. 19, 3817-3827 (2001)
- [57] Gorter, R. W.; van Wely, M.; Reif, M.; et al.: Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern. Ther. Health Med 5, 37-38 (1999)
- [58] Griem, K. L.; Henderson, I. C.; Gelman, R.; Ascoli, D.; Silver, B.; Recht, A.; Goodman, R. L.; Hellman, S.; Harris, J. R.: The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J. Clin. Oncol. 5, 1546-1555 (1997)

- [59] Grossarth-Maticek, R.; Eysenck, H.-J.; Boyle, G. J.; Heeb, J.; Costa, S. D.; Diel, I. J.: Interaction for psychosocial and physical risk factors in the causation of mammary cancer, and its prevention through psychological methods of treatment, *Journal of Clinical Psychology* 56 (1), 33-50 (2000)
- [60] Grossarth-Maticek, R.: Selbstregulation, Autonomie und Gesundheit. Krankheitsfaktoren und soziale Gesundheitsressourcen im sozio-psycho-biologischen System. Walter de Gruyter, Berlin (2003)
- [61] Grossarth-Maticek, R.; Keine, H.; Baumgarner, S. M. and Ziegler, R.: Use of Iscador, an extract of European mistletoe (*Viscum album*), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. *Altern. Ther. Health Med.* 7, 57-78 (2001)
- [62] Grossarth-Maticek, R.; Keine, H.; Baumgartner, S. M.; Ziegler, R.: Use of Iscador, an extract of European mistletoe (*Viscum album*), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. *Alternative Ther.* 7 (3), 57-75 (2001)
- [63] Grossarth-Maticek, R.; Keine, H.; Baumgartner, S. M.; Ziegler, R.: Addendum to Iscador article, *Alternative Therapies Health and Medicine* 7: 57-78 (2001)
- [64] Grossarth-Maticek, R.: Autonomietraining, Gesundheit und Problemlösung durch Anregung der Selbstregulation. Walter de Gruyter, Berlin (2000)
- [65] Grossarth-Maticek, R.; Keine, H.; Baumgartner, S.; Ziegler, R.: Synergieeffekte von Selbstregulation und Misteltherapie (Iscador) auf die Überlebenszeit bei Krebspatienten – Ergebnisse einer epidemiologischen Langzeitstudie, Teil 1, *Schweizerische Zeitschrift für Ganzheitsmedizin* 16 (2), 81-89 (2004)

- [66] Grossarth-Maticek, R.; Kiene, H.; Baumgartner, S.; Ziegler, R.: Richtigstellung seitens der Studienautoren: www.ifaemm.de
- [67] Grossarth-Maticek, R.; Keine, H.; Baumgartner, S.; Ziegler, R.: Verlängerung der Überlebenszeit von Krebspatienten unter Misteltherapie (Iscador) – Ergebnisse einer epidemiologischen Langzeitstudie [Teil1], Schweizerische Zeitschrift für Ganzheitsmedizin 13 (4), 217-225 (2001 c)
- [68] Grothey, A.; Düppe, J.; Hasenburg, A.; Voigtmann, R.: Anwendung alternativmedizinischer Methoden durch onkologische Patienten. Dtsch. Med. Wschr. 123, 923-929 (1998)
- [69] Gutsch, J.; Berger, H.; Scholz, G. and Denck, H.: Prospective study in radically operated breast cancer with polychemotherapy, Helixor and untreated control. Dt. Zschr. Onkol. 21, 94-101 (1988)
- [70] Gutsch, J.; Außergewöhnlicher Krankheitsverlauf bei metastasierendem Mammakarzinom unter Mistelherapie nach pseudoallergischer Reaktion: in: die Mistel in der Tumorthherapie-Grundlagenforschung und Klinik, KVC Verlag, Essen, 379-387 (2001)
- [71] Haberland, J.; Bertz, J.; Görsch, B.; Schön, D.: Krebsinzidenzschätzungen für Deutschland mittels log-linearer Modelle. Gesundheitswesen 63, 556-560 (2001)
- [72] Hajto, T.: Immunomodulatory effects of Iscador: A *Viscum album* preparation. Oncology 43 (1), 51-66 (1986)

- [73] Hajto, T.; Hostanska, K.; Fornalski, M.; Kirsch, A.: Antitumorale Aktivität des immunodulatorisch wirkenden Beta-galaktosid-spezifischen Mistellektins bei der klinischen Anwendung von Mistelextrakten (Iscador). Dtsch. Zuschr. Onkol. 23 (1), (1991)
- [74] Hajto, T.; Hostanska, K.; Saller, R.: Misteltherapie aus der pharmakologischen Perspektive. Forsch. Komplementärmed. 6, 186-194 (1999)
- [75] Hajto, T.; Hostanska, K.: Immunmodulierende Effekte der Misteltherapie. Therapeuticon 3 (6), 361-368 (1989)
- [76] Hanisch, J., Bock, P. R., Karasmann, M.: Standard operating procedures and the operational manual for retrospective cohort studies according to the IFAG-standard, Manual, IFAG Basel AG (2000)
- [77] Harris, J. R.; Halpin-Murphy, P.; Mc Neese, M.: Consensus statement on post-mastectomy radiation therapie. Int J. Radiat Oncol. Biol. Phys. 44, 989-990, (1999)
- [78] Heiny, B. M.: [Additive treatment with standardized mistletoe extract reduces leokopenia and improves the quality of life of patients with advanced carcinoma of the breast getting palliative chemotherapy (VEC regimen)]. Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patienten mit Krebsmedizin 12 [reprint], 1-14 (1991)
- [79] Heiny, B. M.; Beuth, J.: Mistletoe extract standardized for the galactoside specific lectin (ML-I) induces β -endorphin release and immunopotentialiation in breast cancer patients. Anticancer Res. 14, 1339-1342 (1994)

- [80] Heiny, B. M.; Beuth, J.: Mistletoe extract standardized for the galacto-side-specific lectin (ML-1) induces b-endorphin release and immunopotential in breast cancer patients. *Anticancer Res.* 14, 1339-1342 (1994)
- [81] Hellan, J.; Danmayr, E.; Hellan, M.: Stellenwert der Komplementärmedizin in der Behandlung onkologischer Patienten – dargestellt anhand des kolorektalen Karzinoms. *Dtsch. Zschr. Onkol.* 27, 85-94 (1995)
- [82] Hlatky, M. A.; Califf, R. M.; Harrell-FE, Lee, K. L.; Mark, D. B. and Pryor, D. B.: Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. *J. am. Coll. Cardiol.* 11, 237-245 (1988)
- [83] Holtskog, R.; Sandvig, K.; Olsness, S.: Characterization of a Toxic Lectin in Iscador, a Mistletoe Preparation with Alleged Cancerostatic properties, *Oncology* 45, 172-179 (1988)
- [84] Hölzer, D.; Klamer, A.; Schmidt, M.; Krebs – Häufigkeiten, Befunden und Behandlungsergebnisse, Zuckschwerdt Verlag, München (1996)
- [85] Holzner, B.; Kemmler, G.; Kopp, J.; et al.: Quality of life in breast cancer patients – not enough attention for long-term survivors? *Psychosomatics* 42, 117-123 (2001)
- [86] Hornung, J.: Methodisches zu den klinischen Studien zur Misteltherapie des Krebses. *Therapeutikum* 3, 16-21 (1989)
- [87] Huber, R.; Klein, R.; Berg, P. A.; Lüdtker, R.; Werner, M.: Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: A placebo-controlled evaluation in healthy subjects, *J Alternat Complement Med* 8, 857-866 (2002)

- [88] Huber, R.; Thoma, D.; Klein, R.; Berg, P. A.; Lüdtke, R.; Werner, M.: Klinische Wirkungen und Nebenwirkungen eines lektinreichen (Iscador Q spezial) und eines lektinarmen (Iscador Pini) Mistelpräparates – Ergebnisse einer randomisierten, placebo-kontrollierten Phase I Studie bei Gesunden. In: Scheer, R.; Bauer, r.; Becker, H.; Berg, P. A.; Fintelmann, V. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik, KVC Verlag, Essen, 473-484, (2001)
- [89] Huber, R.; Thoma, D; Klein, R.; et al.: Klinische Wirkungen und Nebenwirkungen eines lektinreichen (Iscador Q spezial) und eines lektinarmen (Iscador pini) Mistelpräparates – Ergebnisse einer randomisierten, placebokontrollierten Phase I Studie bei Gesunden. Die Mistel in der Tumortherapie – Grundlagenforschung und Klinik. (Ed. Scheer, R.; Bauer, R.; Becker, H.; et al.,) 473-484, KVC Publishers, Essen (2001)
- [90] Jacobson, J. S.; Workman, S. B.; Kronenberg, F.: Research on complementary / alternative medicine for patients with breast cancer: a review of the biomedical literature. *J. Clin. Oncol.* 18, 668-683 (2000)
- [91] Jüni, P.; Altmann, D. G.; Egger, M.: Assessing the quality of randomised controlled trials. In: Egger, m.; Smith, G. D.; Altmann, D. G. (Eds), *Systematic Reviews in Health Care: Meta-Analysis in Centext*, BMJ Books, London 2. nd edition), 87-108, (2001)
- [92] Khwaja, T. A.; Dias, C. B. and Pentecost, S.: Recent studies on the anticancer activities of mistletoe (*Viscum album*) and its alkaloids. *Oncology* 43 Suppl.1, 42-50 (1986)

- [93] Kiene, H. (2004): Mistel in der Krebstherapie, irreführende Aussagen, Deutsches Ärzteblatt 101 (30): A-2126
- [94] Kiene, H.: Beurteilung klinischer Studien zur Misteltherapie. Grundlagen der Misteltherapie. (Ed. Scheer, R.; Becker, H.; Berg, P. A.) 484-496, Hippokrates Verlag, Stuttgart, Germany (1996)
- [95] Kiene, H.: Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen. Therapeutikum 3, 341-353 (1989)
- [96] Kiene, H.: Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen. Eine Übersicht. Therapeutikum 3, 337-353 (1989)
- [97] Kiene, H.: Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen. Erfahrungsheilkunde 3, 222-227 (1991)
- [98] Kiene, H.; Buschel, G.; Hornebar, M.: [Mistletoe or not mistletoe is still the question]. Forsch. Komplementarmed. Klass. Naturheilkd. 8, 309-312 (2001)
- [99] Kienle, G. S.; Berrino, F.; Büssing, A.; Portalupi, A.; Rosenzweig, S.; Kiene, H.: Mistletoe in cancer – a systematic review on controlled clinical trials. Eur. J. Med. Res. 27, 109-119 (2003)
- [100] Kienle, G. S.; Fiebig, H. H.: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extract in vitro. Anticancer Drugs 13, 373-379 (2003)

- [101] Kienle, G. S.; Kiene, H.: Die Mistel in der Onkologie. Schattauer Verlag. Stuttgart, New York, 1-749 (2003)
- [102] Kishimoto, T (1989): The biology of interleukin-6, *Blood* 74: 1-10
- [103] Kleijnen, J.; Knipschild, P.: Mistletoe treatment for cancer. Review of controlled trials in humans. *Phytomedicine* 1, 255 (1994)
- [104] Kleijnen, J.; Knipschild, P.: Mistletoe treatment for cancer: review of controlled trials in humans. *Phytomedicine* 1, 225-260 (1994)
- [105] Klopp, R.; Schmidt, W.; Niemer, W.; Werner, M.; Beuth, J.: Changes in Immunological Characters of White Blood Cells after Administration of Standardized Mistletoe Extract. *In vivo* 15 (2001)
- [106] Kovacs, E.; Hajto, T.; Hostanka, K.: Improvement of DNA Repair in Lymphocytes of Breast Cancer patients Treated with *Viscum Album* Extract (Iscador). *Eur. J. Cancer* 27 (12), 1672-1676 (1991)
- [107] Kovacs, E.; Kuehn, J.-J.; Werner, M.; Hoffmann, J.: Die Wirkung von *VISCUM ALBUM* (Iscador) auf die DNA-Reparatur in peripheren Lymphozyten nach Gammastrahlen- und Cyclophosphamid-Exposition. Korrelation zur IFN-Gamma-Produktion. *In vitro-Ergebnisse*; 1996. In: *Grundlagen der Misteltherapie*, Scheer, R.; Becker, H.; Berg, A. (eds.), Hippokrates-Verlag, Stuttgart, 197-205 (1996)
- [108] Kreienberg, R.; Möbus, V. Alt, D.: *Management des Mammakarzinoms*, 1-471, Springer Verlag, Heidelberg, Berlin, New York (1998)

- [109] Kröz, M.; Matthes, B.; Brauer, D.; Girke, M.: Eine multidimensionale Erfassung von Tumorverlauf, immunologischen Parametern, vegetativen und konstitutionellen Merkmalen und Lebensqualität bei einer Mammakarzinom-Patientin unter Abnobaviscum. In: Scheer, R.; Bauer, R.; Becker, H.; Berg, P. A.; Fintelmann, V. (Eds): Die Mistel in der Tumorthherapie, KVC Verlag, Essen, 389-402 (2001)
- [110] Kuttan, G.: Reduction of leukopenia in mice by "Viscum Album" administration during radiation and chemotherapy. *Tumor* 79 (1), 74-76 (1993)
- [111] Kuttan, G.; Menon, L.-G.; Kuttan, R.: Prevention of 20-methylcholanthrene-induced sarcoma by a mistletoe extract, Iscador. *Carcinogenesis* 17 (5), 1107-1109 (1996)
- [112] Lenartz, D.; Dott, U.; Menzel, J.; Schierholz, J. M. and Beuth, J.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. *Anticancer Res.* 20, 2073-2076 (2000)
- [113] Leroi, R.: Nachbehandlung des operierten Mammakarzinoms mit *Viscum album*. *Helv Chir Acta* 44, 403-414 (1997)
- [114] Leroi, R.: Resultate der Iscador-Nachbehandlung bei operiertem Mammakarzinom aus der Lukas-Klinik. *Iscador-Informationen. Zur Behandlung des Mammakarzinoms. Verein für Krebsforschung* 1994, (1994)
- [115] Levi, F.; Maisonneuve, Filiberti, R. et al.: Cancer Incidence and Mortality in Europe, *Sozial- und Präventivmed* 34 (Suppl 2), 1-84 (1989)

- [116] Longman, A. J.; Braden, C. J.; Mishel, M. H.: Side effects burden, psychological adjustment, and quality of life in women with breast cancer: pattern of association over time. *Oncol. Nurs. Forum* 26, 909-915 (1999)
- [117] Margolese, R. G.; Fisher, B.; Hortobagyi, G. N. et al.: *Neoplasms of the Breast. Cancer Medicine.* (Ed. Bast, R. C. Jr.; Kufe, D. W.; Pollock, R. E.; et al.) 1735-1822, B. C. Decker In., Hamilton, London (2000)
- [118] Matthes, H.: Onkologische Misteltherapie (*Viscum album L.*) aus klinisch-anthroposophischer Sicht. In: Scheer, R.; Bauer, R.; Berg, P. A.; Fintelmann, V. (Eds.): *Die Mistel in der Tumorthherapie: Grundlagenforschung und Klinik*, KVC Verlag Essen, 253-274 (2001)
- [119] Mc Ardle, C. S.; Crawford, D.; Dykes, E. H. et al.; Adjuvant radiotherapy and chemotherapy in breast cancer. *Br J Surg* 73, 264-266 (1986)
- [120] Mengers, U.; Wittholm, K.; Schwarz, T. and Lentzen, H.: Zur Bedeutung eines auf Mistellektin eingestellten Mistelextraktes für den Nachweis antitumoraler Eigenschaften. *Wien med. Wschr.* 149, 262-362 (1999)
- [121] Michaelis, J.: Bewertung der Umsetzung des Bundeskrebsregistergesetzes und seiner langfristigen Folgen. *Gesundheitswesen* 62, 45-49 (2000)
- [122] Moher, D.; Schulz, K. F.; Altman, D. G.: The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials, *Journal of the American Medical Association* 285, 1987-1991 (2001)
- [123] Moschèn R.; Kemmler G.; Schweigkofler, H.; et al.: Use of alternative / complementary therapy in breast cancer patients – a psychological perspective. *Support Care Cancer* 9, 267-274 (2001)

- [124] Müller, E.-A.; Anderer, F.-A.: Chemical specificity of effector cell/tumor cell bridging by a *Viscum album* rhamnoglycuronan enhancing cytotoxicity of human NK cells. *Immunopharmacology* 19 (1), 69-77 (1990)
- [125] Nikolai, G.; Friedl, P.; Werner, M.; Zänker, K.-S.: Donor-dependent and dosedependant variations in the induction of T lymphocyte locomotion in a three-dimensional collagen matrix system by a mistletoe preparation (Iscador). *Anit-Cancer-Drugs* 8 (suppl. 1), 61-64 (1997)
- [126] Overgaard, M.; Hansen, P. S.; Overgaard, J.; Rose, C.; Andersson, M.; Bach, F.; Kjaer, M.; Gadeber, C. C.; Mouridsen, H. T.; Jensen, M. B.; Zedeler, K.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. *N Engl J Med* 337, 949-955 (1997)
- [127] Oxford Centre for Evidence-based Medicine. Levels of Evidence and Grades of Recommendation. (2001). Ref Type: Internet Communication
- [128] Parkin, D. M.; Muir, C. S.; Whelan, S. C. et al.: Cancer Incidence in Five Continents, IARC Publ, Lyon, Vol. V 1987, Vol. VI 1992, Vol. VII 1997
- [129] Parkin, D. M.; Whelan, S. L.; Ferlay, J.; Raymond, L.; Young, J.: Cancer Incidence in Five Continents Vol. VII, IARC Scientific Publication No. 143, Lyon (1997)
- [130] Partridge, A. H.; Burstein, H. J.; Winer, E. P.: Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. *J. Natl. Cancer Inst. Monographs* 30, 135-142 (2001)

- [131] Piao, B. K.; Wang, Y. X.; Xie, G. R.; Mansmann, U.; Matthes, H.; Beuth, J.; Lin, H. S.: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. *Anticancer Res.* 24, 303-309 (2004)
- [132] Possinger, K.; Grosse, Y.: Präoperative und postoperative adjuvante Behandlung des primären Mammakarzinoms. *Onkologie*, 936-944 (1998)
- [133] Possinger, K.; Schmoll, H. J.; Höffken, K.; Große, Y.: Mammakarzinom der Frau. In: Schmoll, H. J.; Höffken, K.; Possinger, K. (Hrsg). *Kompodium Internistische Onkologie 3. Aufl.* Berlin, Heidelberg, New York: Springer Verlag, 1253-1342 (1999)
- [134] Ragaz, J.; Jackson, S. M.; Le, N.; Plenderleith, I. H.; Spinelli, J. J.; Basco, V. E.; Wilson, K. S.; Knowling, M. A.; Coppin, C. M.; Paradis, M.; Coldman, A. J.; Olivotto, I. A.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. *N. Engl. J. Med.* 337, 956-962 (1997)
- [135] Rentea, R. et al.: Biologic Properties of Iscador: A *Viscum album* Preparation. I. Hyperplasia of the Thymic Cortex and Accelerated Regeneration of Hemopoietic Cells following X-Irradiation. *Laboratory Investigation* 44 (1), 43-48 (1981)
- [136] Richter, E. A.: Krebsregistrierung in Deutschland, *Deutsches Ärzteblatt* 97, A1286-1290, (2000)

- [137] Rosati, R.A.; Lee, K.L.; Califf, R.M.; Pryor, D.B., Harrell, F.E.: Problems and advantages of an observational Data Base Approach to Evaluating the Effect of Therapy on Outcome. *Circulation* 65 (Suppl.II), 27-32, (1982)
- [138] Sauer, R.; Schulz, K. D.; Hellriegel, K. P.: Radiation Therapy after Mastectomy – Interdisciplinary Consensus Puts and End to a Controversy. *Strahlenther. Onkol.* 177, 1-9 (2001)
- [139] Schneider, B.: Analysis of therapeutic efficacy in observational cohort studies. *Cancer Chemother. Pharmacol.* 47, 35-37 (2001)
- [140] Schneider, B.: Analysis of therapeutic efficacy in observational cohort studies. *Cancer Chemother. Pharmacol.* 47, 35-37 (2001)
- [141] Schön, D.; Bertz, J.; Hoffmeister, H. (Hrsg): *Bevölkerungsbezogene Register in der Bundesrepublik Deutschland Bd. 3*, MMV, München (1995)
- [142] Schottenfeld, D.; Fraumeni, J. F. (Hrsg): *Cancer Epidemiology and Prevention*. Oxford University Press, New York (1996)
- [143] Schumacher, K.: *Therapie maligner Tumoren*, Stuttgart, Schattauer Verlag (2000)
- [144] Schumacher, K.; Schneider, B.; Reich, G.; Stiefel, T.; Stoll, G.; Bock, P. R.; Hanisch, J. J.: [Post surgical complementary therapy of primary breast carcinoma with a lectin-standardized mistletoe extract – an epidemiological, controlled, multicenter, retrospective cohort study.]. *German Journal of Oncology* 34, 106-114, (2002)

- [145] Schumacher, U.; Stamouli, A.; Adam, E. et al.: Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II and III with human breast cancer cell lines. *Glycoconj. J.* 12, 250 (1995)
- [146] Schütz, J., Schön, D., Baumgardt-Elms, C, Eisinger, B, Lehnert, M, Stegmaier, C.: Cancer registration in Germany: current status, perspectives and trends in cancer incidence from 1973 to 1993. A report from the Network of German Population based Cancer Registries. *J. Epidemiol. Biostat.* 5, 99-107 (2000)
- [147] Schwabe, U.; Paffrath, D.: *Arzneiverordnungsreport 2003*, 548-550, Springer, Berlin, Heidelberg, New York (2004)
- [148] Schwaibold, F.; Fowble, B. L.; Solin, L. J.; Schultz, D. J.; Goodman, R. L.: The results of radiation therapy for isolated local regional recurrence after mastectomy. *Int. J. Radiat. Oncol. Bio. Phys.* 21, 299-310 (1991)
- [149] Shapiro, C. L.; Recht, A.: Side Effects of Adjuvant Treatment of Breast Cancer. *N. Engl. J. Med.* 344, 1997-2008 (2001)
- [150] Staak, J. O.; Stoffel, B.; Wagner, H.; Pulverer, G.; Beuth, J.: In-vitro-Zytotoxizität der *Viscum album* Agglutinine I und II. *Z. Onkol.* 30, 29-33 (1998)
- [151] Stein, G. M. and Berg, P. A.: Adverse effects during therapy with mistletoe extracts. In *Mistletoe. The Genus Viscum.* (Ed. Büssing, A.) 195-208, Harwood Academic Publishers, Australia, Canada, France, Germany, etc. (2000)
- [152] Stein, G. M.: Toxicology of Mistletoe Extracts and their Components. *Mistletoe. The Genus Viscum.* (Ed. Büssing, a.) 183-193, Haarwood Academic Publishers, Amsterdam (2000)

- [153] Stein, G. M.; Berg, P. A.: Evaluation of a fermented mistletoe lectin-1 free mistletoe extract on T-helper cells and monocytes in healthy individuals in vitro, *Arzneim-Forsch/Drugs* 8 (Suppl 1), 57-59, (1996)
- [154] Stein, G. M.; Büssing, A.; Schietzel, M.: Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract, *Anticancer. Res.* 22, 4215-4219 (2002)
- [155] Stein, G. M.; Henn, W.; von Laue, H. B.; Berg, P. A.: Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy, *Eur. J. Med. Res.* 3, 94-202 (1998)
- [156] Stein, G.; Berg, P.-A.: Non-lectin component in a fermented extract from *Viscum album* L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. *Eur. J. Clin. Pharmacol.* 47, 33-38 (1994)
- [157] Stein, G.; Henn, W.; von Laue, P.; Berg, P.A. (1997): Induction of antimistletoe lectin antibodies in relation to different mistletoe extracts, *anticancer – Drugs* 8 (supp 1): 57- 59
- [158] Steuer-Vogt, M. K., Bonkowsky, V.; Ambrosch, P.; Scholz, M.; Neiss, A.; Strutz, J.; Hennig, M.; Lenarz, T. and Arnold, W.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. *Eur. J. Cancer* 37, 23-31 (2001)
- [159] Stirpe, F. et al: Inhibition of protein synthesis by a toxic lectin from *Viscum album* L. (mistletoe). *Biochem. J.* 843-845 (1980)

- [160] Stoffel, B.; Beuth, J.; Pulverer, G.: Effect on immunomodulation with galactoside-specific mistletoe lectin on experimental listeriosis. *Zbl. Bakt.* 284, 439-442 (1996)
- [161] Tabiasco, J., Pont, F. Fornie, J.J., Vercellone, A. Mistletoe increase natural killer-cell mediated cytotoxicity, *Eur. J. Biochem*, 269, 2591-2600, (2002)
- [162] van Wely, M.; Stoss, M.; Gorter, R. W.: Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals. *Am. J. Ther.* 6, 37-43 (1999)
- [163] Verones, U.; Marubini, E.; Mariani, L. et al: Radiotherapy after breast-conserving surgery in small breast carcinoma: Long term results of a randomized trial. *Ann. Oncol.* 12, 997-1003 (2001)
- [164] Vester, F.: Über die kanzerostatischen und immunogenen Eigenschaften von Mistelproteinen. *Krebsgeschehen* 9 (5), 106-114 (1977)
- [165] Wetzell, D.: Results of a randomized placebo-controlled multicentre study with PS76A2 (standardized mistletoe preparation) in patients with breast cancer receiving chemotherapy. *Phytomedicine* 7 [Supplement 2], 34 (2000) Ref. Type: Abstract
- [166] Weiss, J., Bartsch, H., Hennies, F., Rietschel, M., Henn, M., Adam, G., Görtner, U., Ammon, A., (1998): Complementary medicine in Cancer Patients, *Oncology*: 21:144-149
- [167] Whelan, T. J.; Wright, J.; Jadad, J. R.; Levine, M. L.: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. *J. Clin. Oncol.* 18, 1220-1229 (2000)

- [168] Wood, A. J.; Hortobagyi, G. N.: Treatment of cancer. *New Engl. J. Med.* 339, 974-984 (1998)